Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States

Disclosures: Benedict is an employee of Evidera, which has previously received consulting and research fees from Pfizer, among other pharmaceutical, device, government, and nongovernment organizations. She has not received compensation for her participation in development of this letter. Ramaswamy and Sandin are employed by Pfizer. Medical writing support was provided by Andy Gannon at ACUMED—an Ashfield company, part of UDG Healthcare plc, New York, NY—with funding from Pfizer.